Researchers at the VIB-UGent Center for Medical Biotechnology have discovered a promising strategy to improve treatment ...

Researchers at the VIB-UGent Center for Medical Biotechnology have discovered a promising strategy to improve treatment ...

LONDON, UK I April 17, 2025 I GSK plc (LSE/NYSE: GSK) today announced the authorisation of Blenrep by the Medicines and Healthcare products Regulatory Agency ...

Melphalan flufenamide (melflufen) is approved in Europe for relapsed/refractory multiple myeloma, but the FDA withdrew its ...

Researchers sought to evaluate preferences related to treatment features of BCMA-directed bispecific antibodies and CAR-T therapy.

CAR T-cell therapy reprograms a patient's immune cells to target and destroy cancer cells, offering a promising treatment for ...

The U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) on Thursday authorized GSK plc’s (NYSE:GSK) Blenrep.

Hematologist-oncologist Mateo Mejia Saldarriaga, MD, combines clinical care with research aimed at helping patients with ...

GSK has secured the first regulatory approval for Blenrep since the antibody-drug conjugate’s global market withdrawal in ...

During a live event, Kathleen A. Dorritie, MD, discussed updated outcomes from the GRIFFIN and PERSEUS clinical trials of quadruplet therapy in multiple myeloma.

Legend Biotech (LEGN) shares jumped 5% over the past week on heavy trading volume as investors responded to impressive ...